CYP3A (m): 293T Lysate: sc-119596



The Power to Question

BACKGROUND

CYP3A genes encode monooxygenases, enzymes which catalyze drug metabolism and the synthesis of cholesterol, steroids and other lipids. CYP3A (cytochrome P450, family 3, subfamily A), the most abundant p450 enzyme in human liver, is responsible for the metabolism of more than 50% of all clinical drugs. CYP3A members localize in organs that associate with drug disposition, including the liver, gastrointestinal tract and kidney. The CYP3A cluster consists of four genes: CYP3A43, CYP3A4, CYP3A7 and CYP3A5, and two pseudogenes: CYP3A5P1 and CYP3A5P2. The CYP3A cluster maps to gene locus 7q22.1.

REFERENCES

- Paulussen, A., et al. 2000. Two linked mutations in transcriptional regulatory elements of the CYP3A5 gene constitute the major genetic determinant of polymorphic activity in humans. Pharmacogenetics 10: 415-424.
- Online Mendelian Inheritance in Man, OMIM™. 2002. Johns Hopkins University, Baltimore, MD. MIM Number: 606534. World Wide Web URL: http://www.ncbi.nlm.nih.gov/omim/
- 3. Williams, P.A., et al. 2004. Crystal structures of human cytochrome P450 3A4 bound to metyrapone and progesterone. Science 305: 683-686.
- Stedman, C., et al. 2004. Feed-forward regulation of bile acid detoxification by CYP3A4: studies in humanized transgenic mice. J. Biol. Chem. 279: 11336-11343.
- Hidaka, M., et al. 2006. Transient inhibition of CYP3A in rats by star fruit juice. Drug Metab. Dispos. 34: 343-345.
- Mueller, S.C., et al. 2006. The extent of induction of CYP3A by St. John's wort varies among products and is linked to hyperforin dose. Eur. J. Clin. Pharmacol. 62: 29-36.
- 7. Persson, K.P., et al. 2006. Evaluation of human liver slices and reporter gene assays as systems for predicting the cytochrome P450 induction potential of drugs *in vivo* in humans. Pharm. Res. 23: 56-69.
- 8. LocusLink Report (LocusID: 1574). http://www.ncbi.nlm.nih.gov/LocusLink/

PRODUCT

CYP3A (m): 293T Lysate represents a lysate of mouse CYP3A transfected 293T cells and is provided as 100 μg protein in 200 μl SDS-PAGE buffer.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

APPLICATIONS

CYP3A (m): 293T Lysate is suitable as a Western Blotting positive control for mouse reactive CYP3A antibodies. Recommended use: 10-20 µl per lane.


Control 293T Lysate: sc-117752 is available as a Western Blotting negative control lysate derived from non-transfected 293T cells.

CYP3A (D-2): sc-271033 is recommended as a positive control antibody for Western Blot analysis of enhanced mouse CYP3A expression in CYP3A transfected 293T cells (starting dilution 1:100, dilution range 1:100-1:1,000).

RECOMMENDED SUPPORT REAGENTS

To ensure optimal results, the following support reagents are recommended: 1) Western Blotting: use m-lgG κ BP-HRP: sc-516102 or m-lgG κ BP-HRP (Cruz Marker): sc-516102-CM (dilution range: 1:1000-1:10000), Cruz MarkerTM Molecular Weight Standards: sc-2035, UltraCruz[®] Blocking Reagent: sc-516214 and Western Blotting Luminol Reagent: sc-2048.

DATA



CYP3A (D-2): sc-271033. Western blot analysis of CYP3A expression in non-transfected: sc-117752 (A) and mouse CYP3A transfected: sc-119596 (B) 293T whole rell I visates

STORAGE

Store at -20° C. Repeated freezing and thawing should be minimized. Sample vial should be boiled once prior to use. Non-hazardous. No MSDS required.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.

Santa Cruz Biotechnology, Inc. 1.800.457.3801 831.457.3800 fax 831.457.3801 Europe +00800 4573 8000 49 6221 4503 0 www.scbt.com